AC Immune Reports Positive Phase II Safety Data for Parkinson’s Vaccine Candidate
AC Immune said the first stage of its VacSYn Phase II study for ACI-7104.056 achieved its main safety, tolerability, and immune-response goals in early Parkinson’s disease. All 25 participants who received the immunotherapy developed antibodies against aggregated alpha-synuclein, and antibodies were detected in cerebrospinal fluid. The 34-person trial was not designed to prove efficacy, but the company plans a larger Part 2 study and longer follow-up.
AC Immune’s VacSYn Phase II Part 1 tested ACI-7104.056, an active immunotherapy for early Parkinson’s disease. The placebo-controlled trial enrolled 34 people: 25 received the candidate and nine received placebo. Treatment lasted 18 months, followed by six months of safety monitoring. All treated participants produced antibodies after three vaccinations, with levels rising after later doses; placebo recipients showed no detectable response. Antibodies also appeared in cerebrospinal fluid among all treated participants.
Common side effects included injection-site reactions, headache, and fatigue. The safety board advised continuing without changes. Although exploratory biomarker and motor-score trends favored treatment, the small study could not establish efficacy. AC Immune plans quarterly dosing studies, follow-up up to four years, and a roughly 250-patient Part 2 trial, with FDA discussions and a possible start in the first half of the next year.
Count first para: AC(1) Immune’s2 VacSYn3 Phase4 II5 Part6 1? "1" maybe 7 tested8 ACI-7104.056,9 an10 active11 immunotherapy12 for13 early14 Parkinson’s15 disease.16 The17 placebo-controlled18 trial19 enrolled20 34 21 people:22 25 23 received24 the25 candidate26 and27 nine28 received29 placebo.30 Treatment31 lasted32 18 33 months,34 followed35 by36 six37 months38 of39 safety40 monitoring.41 All42 treated43 participants44 produced45 antibodies46 after47 three48 vaccinations,49 with50 levels51 rising52 after53 later54 doses;55 plac
If later studies confirm these early signals, an alpha-synuclein vaccine could eventually offer Parkinson’s patients and families a new disease-modifying option, though many years of testing remain. It may also influence how clinicians discuss experimental therapies and how investors view neurodegenerative research. Should efficacy fail, hopes could be tempered, but the safety and immune-response data may still guide future trials. Access, cost, and long-term benefit remain uncertain and would depend on larger results and regulatory review. Count: If1 later2 studies3 confirm4 these5 early6 signals,7 an8 alpha-synuclein9 vaccine10 could11 eventually12 offer13 Parkinson’s14 patients15 and16 families17 a18 new19 disease-modifying20 option,21 though22 many23 years24 of25 testing26 remain.27 It28 may29 also30 influence31 how32 clinicians33 discuss34 experimental35 therapies36 and37 how38 investors39 view40 neurodegenerative41 research.42 Should43 efficacy44 fail,45 hopes46 could47 be48 tem